

Socioeconomic and Geographic Access to Novel Therapeutics: An Analysis of Growth in Transcatheter Aortic Valve Replacement Programs

Ashwin Nathan MD, MS

04.28.2021



SCAI

Society for Cardiovascular
Angiography & Interventions

Novel Technologies

- Advances in biotechnology have permitted *rapid* therapeutic advancements
- However, the initial growth of a procedure may not be distributed **equitably**
- **Inequities** in access to healthcare results in **health inequities**



SCAI

Society for Cardiovascular
Angiography & Interventions

Study Aims

We sought to understand:

- 1. Areas** where new TAVR programs are established
- 2. Patient populations** served by new TAVR programs
- 3. Rates** of TAVR among differing patient populations



SCAI

Society for Cardiovascular
Angiography & Interventions

Findings

1. Increased # of TAVR programs ≠ **Increased Access**
 - TAVR sites are localized to metropolitan areas
 - Majority of TAVR sites opened in areas with pre-existing programs
2. Hospitals adopting TAVR served **more advantaged patients**
 - Wealthy, more privileged patients had more access to TAVR by virtue of the hospitals that served them
3. Rates of TAVR are higher in more **socioeconomically advantaged patients**
 - Inequities in access to TAVR translated into lower rates of TAVR among socioeconomically disadvantaged groups



SCAI

Society for Cardiovascular
Angiography & Interventions

Future Directions

1. Identify the role of **race and ethnicity** in inequitable access to TAVR
2. Identify **system- and patient-level barriers** in access
3. Develop and test **solutions** to address inequitable care



SCAI

Society for Cardiovascular
Angiography & Interventions